Table 4.
Incidence Rate and Hazard Ratio (HR) of Advanced Chronic Kidney Disease (CKD) Among Adults With and Without Neurodevelopmental Disabilities (NDDs) Stratified by Age and Sex
| Advanced CKD Cases | Crude Incidence Rate | Incidence Rate Ratio (IRR) | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|---|---|
| N | N per 1000/Years (95% CI) | IRR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| Age-stratified analysis | ||||||
| 18–39 years | ||||||
| Without NDDs | 1725 | 0.41 (0.39, 0.43) | Reference | Reference | Reference | Reference |
| With NDDs | 74 | 1.68 (1.30, 2.07) | 4.14 (3.28, 5.22) | 4.99 (3.95, 6.31) | 3.83 (3.03, 4.84) | 3.74 (2.96, 4.74) |
| 40–64 Years | ||||||
| Without NDDs | 17,848 | 2.53 (2.49, 2.57) | Reference | Reference | Reference | Reference |
| With NDDs | 273 | 7.62 (6.71, 8.52) | 3.01 (2.67, 3.39) | 3.00 (2.66, 3.38) | 2.32 (2.06, 2.61) | 2.09 (1.85, 2.36) |
| ≥65 years | ||||||
| Without NDDs | 88,442 | 14.71 (14.61, 14.80) | Reference | Reference | Reference | Reference |
| With NDDs | 465 | 25.21 (22.92, 27.50) | 1.71 (1.56, 1.88) | 1.74 (1.59, 1.91) | 1.65 (1.51, 1.81) | 1.51 (1.38, 1.65) |
| Sex-stratified analysis | ||||||
| Women | ||||||
| Without NDDs | 53,940 | 5.69 (5.64, 5.74) | Reference | Reference | Reference | Reference |
| With NDDs | 359 | 8.30 (7.44, 9.16) | 1.46 (1.31, 1.62) | 2.09 (1.88, 2.31) | 1.87 (1.68, 2.07) | 1.70 (1.53, 1.88) |
| Men | ||||||
| Without NDDs | 54,075 | 6.90 (6.85, 6.96) | Reference | Reference | Reference | Reference |
| With NDDs | 453 | 8.24 (7.48, 9.00) | 1.19 (1.09, 1.31) | 2.27 (2.07, 2.49) | 2.13 (1.94, 2.33) | 1.97 (1.79, 2.16) |
Note: Reference indicates that the group was set as the reference to derive the effect estimates for the other groups.
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; Model 1, age (as continuous), sex (except for sex-stratified analyses), and US region; Model 2, model 1 variables and baseline hypertension and diabetes; Model 3, model 2 variables and baseline ischemic heart disease, heart failure, and cerebrovascular disease.